North America Oncology Based Molecular Diagnostics Market Size & Outlook
North America oncology based molecular diagnostics market, 2018-2030 (US$M)
Related Markets
North America oncology based molecular diagnostics market highlights
- The North America oncology based molecular diagnostics market generated a revenue of USD 1,185.8 million in 2023.
- The market is expected to grow at a CAGR of 10.5% from 2024 to 2030.
- In terms of segment, instruments was the largest revenue generating product in 2023.
- Instruments is the most lucrative product segment registering the fastest growth during the forecast period.
North America data book summary
| Market revenue in 2023 | USD 1,185.8 million |
| Market revenue in 2030 | USD 2,378.5 million |
| Growth rate | 10.5% (CAGR from 2023 to 2030) |
| Largest segment | Instruments |
| Fastest growing segment | Instruments |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Instruments |
| Key market players worldwide | Abbott Laboratories, Bayer AG, BD, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Qiagen NV, Roche, Siemens AG, Sysmex Corp |
Other key industry trends
- In terms of revenue, North America region accounted for 43.9% of the global oncology based molecular diagnostics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,689.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology based Molecular Diagnostics Market Scope
Oncology based Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America oncology based molecular diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based molecular diagnostics market will help companies and investors design strategic landscapes.
Instruments was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the North America oncology based molecular diagnostics market based on instruments covering the revenue growth of each sub-segment from 2018 to 2030.
Although blood testing and clinical chemistry IVDs are mature markets in North America and are anticipated to grow at a decent rate over the next decade, molecular diagnostics is the fastest growing market in the region. Molecular diagnostics provide accuracy, sensitivity, and specificity, leading to a rapid increase in its demand.
Rising need for genetic testing for personalized healthcare in disease areas, such as diabetes and cancer, is expected to further drive the market. There has been an increase in the number of strategic partnerships between major pharmaceuticals and in vitro diagnostic manufacturing companies to develop companion diagnostics, thus creating lucrative opportunities in this region.
Reasons to subscribe to North America oncology based molecular diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America oncology based molecular diagnostics market databook
-
Our clientele includes a mix of oncology based molecular diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America oncology based molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into North America oncology based molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America oncology based molecular diagnostics market
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
